In vivo gene editing is a form of gene editing in which the editing machinery is delivered directly into the patient's body and changes DNA in cells where they are. The main entry explains the underlying technologies. In vivo is Latin for within the living.
The contrasting approach is ex vivo editing. There, cells such as blood stem cells are taken from the patient, edited in a laboratory, checked and infused back, a process that needs specialised centres and often harsh preparatory treatment. In vivo editing avoids those steps: the therapy is given as an infusion or injection, in principle like a conventional drug. The editing components are carried to their target by a delivery vehicle, most often tiny fat particles or a modified virus.
Delivery is the main technical limit. The liver takes up these vehicles readily, so early programmes have focused on liver-related diseases, and reaching other organs is harder. Because edits made inside the body cannot be inspected or withdrawn, regulators look closely at unintended changes to DNA and at long-term safety. For investors in genomics, the approach is significant because simpler treatment could reach far more patients and bring a functional cure within reach for common conditions. Most programmes remain in clinical trials, a field also shaped by AI-developed drugs.